University of Oxford

Broad-spectrum chemokine-neutralising peptides as therapeutics for autoimmune disease

University of Oxford have developed short peptides able to bind and neutralise the chemokine signalling network involved in inflammation. The peptides were developed from naturally occurring tick salivary proteins and functionalised using a rational drug design approach. Multi/Pan-chemokine inhibition aims to selectively inhibit pathological (autoimmune and) inflammatory responses without compromising wider immunity.



2024 finalists

Take a look at the finalists across the four competition categories